Episode 258: IMPROVE-IT – ezetimibe, what it does and doesn’t do
In episode 258, James and Mike discuss the very recently released IMPROVE-IT study that was presented November 17th, 2014 at the AHA meeting. We discuss what was found and what wasn’t found and whether or not these results lend credence to the lipid hypothesis. We find that finally a drug used to change a surrogate marker actually appears to reduce cardiovascular events (we have had 20 negative trials in a row before this) but the magnitude is certainly not huge. We discuss the nuances of the results and hopefully put it into a reasonable perspective.